Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1992 Jan;30(1):149–153. doi: 10.1128/jcm.30.1.149-153.1992

Serotype prevalence of Candida albicans from blood culture isolates.

D L Brawner 1, G L Anderson 1, K Y Yuen 1
PMCID: PMC265011  PMID: 1734047

Abstract

Blood culture isolates of Candida albicans were collected from 102 patients in Seattle, Wash., hospitals (n = 77) and Hong Kong (n = 25). The patients were classified by immune status into two groups. Group I patients were severely immunosppression, and group II patients had underlying risk factors for candidemia but no underlying immunosuppression. Serotyping by Hasenclever tube agglutination was done. In the Seattle area, the odds of fungemia with type B C. albicans were 3.62 times greater than the odds of type B fungemia in group II patients. Although the odds ratio could not be computed for Hong Kong patients, the direction of the relationship in this population was consistent with the data on Seattle patients. Despite the magnitude of the odds ratios, the relative prevalence of type B over type A in group I compared with group II was not significant when analyzed separately by region, probably because of relatively low numbers of isolates in group II. Accepting that the effect of immune status on serotype is equivalent across regions but presupposing that a regional effect on type B prevalence exists, the pooled odds for fungemia with serotype B in group I patients are increased 5.4-fold over those of group II patients. Logistic regression analysis controlling for region gave similar results.

Full text

PDF
149

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auger P., Dumas C., Joly J. A study of 666 strains of Candida albicans: correlation between serotype and susceptibility to 5-fluorocytosine. J Infect Dis. 1979 May;139(5):590–594. doi: 10.1093/infdis/139.5.590. [DOI] [PubMed] [Google Scholar]
  2. Bodey G. P., Anaissie E. J. Chronic systemic candidiasis. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):855–857. doi: 10.1007/BF01963770. [DOI] [PubMed] [Google Scholar]
  3. Brawner D. L. Comparison between methods for serotyping of Candida albicans produces discrepancies in results. J Clin Microbiol. 1991 May;29(5):1020–1025. doi: 10.1128/jcm.29.5.1020-1025.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brawner D. L., Cutler J. E. Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome. J Clin Microbiol. 1989 Jun;27(6):1335–1341. doi: 10.1128/jcm.27.6.1335-1341.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brawner D. L., Cutler J. E. Variability in expression of a cell surface determinant on Candida albicans as evidenced by an agglutinating monoclonal antibody. Infect Immun. 1984 Mar;43(3):966–972. doi: 10.1128/iai.43.3.966-972.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bross J., Talbot G. H., Maislin G., Hurwitz S., Strom B. L. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med. 1989 Dec;87(6):614–620. doi: 10.1016/s0002-9343(89)80392-4. [DOI] [PubMed] [Google Scholar]
  7. Drouhet E., Mercier-Soucy L., Montplaisir S. Sensibilité et résistance des levures pathogènes aux 5-fluoropyrimidines. I.--Relation entre les phénotypes de résistance a la 5-fluorocytosine, le sérotype de Candida albicans et l'écologie de différentes espèces de Candida d'origine humaine. Ann Microbiol (Paris) 1975 Jul-Aug;126B(1):25–39. [PubMed] [Google Scholar]
  8. Firon N., Ashkenazi S., Mirelman D., Ofek I., Sharon N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun. 1987 Feb;55(2):472–476. doi: 10.1128/iai.55.2.472-476.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. HASENCLEVER H. F., MITCHELL W. O. Antigenic studies of Candida. I. Observation of two antigenic groups in Candida albicans. J Bacteriol. 1961 Oct;82:570–573. doi: 10.1128/jb.82.4.570-573.1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. HASENCLEVER H. F., MITCHELL W. O. Antigenic studies of Candida. III. Comparative pathogenicity of Candida albicans group A, group B, and Candida stellatoidea. J Bacteriol. 1961 Oct;82:578–581. doi: 10.1128/jb.82.4.578-581.1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Horn R., Wong B., Kiehn T. E., Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985 Sep-Oct;7(5):646–655. doi: 10.1093/clinids/7.5.646. [DOI] [PubMed] [Google Scholar]
  12. Hunter P. R. A critical review of typing methods for Candida albicans and their applications. Crit Rev Microbiol. 1991;17(6):417–434. doi: 10.3109/10408419109115206. [DOI] [PubMed] [Google Scholar]
  13. Karabinis A., Hill C., Leclercq B., Tancrède C., Baume D., Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol. 1988 Mar;26(3):429–432. doi: 10.1128/jcm.26.3.429-432.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Katz S. J., Wenger N. S., Shapiro M. F. Diagnostic value of bacterial and fungal blood cultures in patients with the acquired immunodeficiency syndrome. Am J Med. 1990 May;88(5N):28N–32N. [PubMed] [Google Scholar]
  15. Korting H. C., Ollert M., Georgii A., Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol. 1988 Dec;26(12):2626–2631. doi: 10.1128/jcm.26.12.2626-2631.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mahrous M., Lott T. J., Meyer S. A., Sawant A. D., Ahearn D. G. Electrophoretic karyotyping of typical and atypical Candida albicans. J Clin Microbiol. 1990 May;28(5):876–881. doi: 10.1128/jcm.28.5.876-881.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Matthews R., Burnie J., Smith D., Clark I., Midgley J., Conolly M., Gazzard B. Candida and AIDS: evidence for protective antibody. Lancet. 1988 Jul 30;2(8605):263–266. doi: 10.1016/s0140-6736(88)92547-0. [DOI] [PubMed] [Google Scholar]
  18. Meunier-Carpentier F., Kiehn T. E., Armstrong D. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med. 1981 Sep;71(3):363–370. doi: 10.1016/0002-9343(81)90162-5. [DOI] [PubMed] [Google Scholar]
  19. Meyers J. D. Fungal infections in bone marrow transplant patients. Semin Oncol. 1990 Jun;17(3 Suppl 6):10–13. [PubMed] [Google Scholar]
  20. Pfaller M., Cabezudo I., Koontz F., Bale M., Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol. 1987 Dec;6(6):628–633. doi: 10.1007/BF02013057. [DOI] [PubMed] [Google Scholar]
  21. Pizzo P. A., Robichaud K. J., Gill F. A., Witebsky F. G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982 Jan;72(1):101–111. doi: 10.1016/0002-9343(82)90594-0. [DOI] [PubMed] [Google Scholar]
  22. Reagan D. R., Pfaller M. A., Hollis R. J., Wenzel R. P. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol. 1990 Dec;28(12):2733–2738. doi: 10.1128/jcm.28.12.2733-2738.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Richet H. M., Andremont A., Tancrede C., Pico J. L., Jarvis W. R. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis. 1991 Mar-Apr;13(2):211–215. doi: 10.1093/clinids/13.2.211. [DOI] [PubMed] [Google Scholar]
  24. Shadomy S., Shadomy H. J. Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans. Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):21–22. doi: 10.1016/0732-8893(91)90082-q. [DOI] [PubMed] [Google Scholar]
  25. Soll D. R., Langtimm C. J., McDowell J., Hicks J., Galask R. High-frequency switching in Candida strains isolated from vaginitis patients. J Clin Microbiol. 1987 Sep;25(9):1611–1622. doi: 10.1128/jcm.25.9.1611-1622.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stevens D. A., Odds F. C., Scherer S. Application of DNA typing methods to Candida albicans epidemiology and correlations with phenotype. Rev Infect Dis. 1990 Mar-Apr;12(2):258–266. doi: 10.1093/clinids/12.2.258. [DOI] [PubMed] [Google Scholar]
  27. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother. 1982 Sep;22(3):482–487. doi: 10.1128/aac.22.3.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Weese-Mayer D. E., Fondriest D. W., Brouillette R. T., Shulman S. T. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J. 1987 Feb;6(2):190–196. doi: 10.1097/00006454-198702000-00009. [DOI] [PubMed] [Google Scholar]
  29. Whelan W. L., Kirsch D. R., Kwon-Chung K. J., Wahl S. M., Smith P. D. Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel of hypervirulent strain. J Infect Dis. 1990 Aug;162(2):513–518. doi: 10.1093/infdis/162.2.513. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES